What is a generic drug, and is it really the same medicine?

A generic drug is a medicine containing the same active ingredient as an originally branded product, in the same strength and dosage form, taken by the same route, and intended to work the same way. It is made by a different manufacturer, sold under the ingredient’s name rather than a brand name, and is usually far cheaper.

This article explains how generics are regulated and why they cost less. It is not medical advice, and questions about a specific medicine belong with a pharmacist or doctor who knows your history.

Why they only appear after a delay

Developing a new medicine is expensive and mostly unsuccessful — the great majority of candidate compounds fail somewhere between the laboratory and the clinic, and the cost of the failures is carried by the few that succeed. Patents exist to make that arithmetic survivable, granting the originator a period during which no one else may sell the compound.

Regulators typically add a separate protection called data exclusivity, which prevents other manufacturers relying on the originator’s clinical trial data for a defined period. The two run in parallel and do not necessarily expire together, which is why the arrival of generic competition is often a legally contested date rather than an obvious one.

Once both lapse, other manufacturers may apply to sell the same active ingredient. Competition usually follows quickly, and prices commonly fall sharply once several suppliers are in the market.

What a generic manufacturer must prove

A generic application does not repeat the full programme of clinical trials, and this is the single biggest reason for the price difference. The originator already established that the active ingredient is safe and effective; requiring every subsequent manufacturer to demonstrate that again would mean giving some trial participants a treatment already known to work, at enormous cost and for no new knowledge.

What the applicant must show instead is bioequivalence: that its version delivers the active ingredient into the bloodstream at essentially the same rate and to the same extent as the reference product. This is tested directly, usually in healthy volunteers, by measuring drug concentrations over time and comparing the resulting curves against the original within a defined statistical range.

The manufacturer must also meet the same manufacturing standards as any other pharmaceutical producer, and its facilities are subject to inspection. A generic is a regulated pharmaceutical product, not an unbranded approximation of one.

What can legitimately differ

Generics are usually required to look unlike the brand, because trade dress is itself protected. Colour, shape, size and markings therefore differ, which is why a repeat prescription can arrive looking unfamiliar — a common source of worry, and normally not a sign that anything is wrong.

Inactive ingredients may also differ: binders, fillers, preservatives, dyes and coatings. These are not pharmacologically active, but they are not nothing. A patient with a specific allergy or intolerance can react to an excipient, and that is a genuine reason to check a formulation rather than assume equivalence in every respect.

The category also has edges. Modified-release formulations, inhalers and topical products are harder to copy exactly, because delivery depends on the physical construction and not only the compound. And biological medicines — large molecules grown in living cells — cannot be replicated identically at all; their follow-on versions are called biosimilars and are regulated under a distinct and more demanding pathway.

Why the price gap is so large

A generic manufacturer avoids the research that failed, the trials that succeeded, and the marketing that built the brand. It enters a market where the clinical case is already made and prescribers already know the drug, and it competes largely on price against others doing the same.

Competition compounds the effect. The first generic to market typically enters below the brand price but well above cost; as further manufacturers are approved, the price tends to fall much further, which is why savings usually deepen over the years after a patent expires rather than arriving all at once.

The saving is substantial enough that generics are central to how health systems remain affordable, and they account for the large majority of prescriptions dispensed in many countries while representing a far smaller share of total spending. Public health bodies treat quality-assured generics as fully interchangeable with originator products for most purposes — which is a statement about the strength of the regulatory requirement, not a compromise made for the sake of cost.